Randomized Phase III Trial of Pegfilgrastim versus Filgrastim after Autologus Peripheral Blood Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 5, 2010, Pages 678-685

  Gerds, Aaron ^a   Fox Geiman, Mary ^b   Dawravoo, Kevin ^a   Rodriguez, Tulio ^a   Toor, Amir ^a   Smith, Scott ^a   Kiley, Karen ^b   Fletcher Gonzalez, Donna ^b   Hicks, Chindo ^a   Stiff, Patrick ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Autologous stem cell transplantation; Hematopoietic engraftment; Pegfilgrastim

Indexed keywords

ACICLOVIR; BUSULFAN; CARBOPLATIN; CARMUSTINE; CILASTATIN PLUS IMIPENEM; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; IFOSFAMIDE; MELPHALAN; MITOXANTRONE; NORFLOXACIN; PACLITAXEL; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BACTERIUM CULTURE; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ENGRAFTMENT; FATALITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOCYTE TRANSFUSION; WHOLE BODY RADIATION;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; COSTS AND COST ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; FILGRASTIM; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REGENERATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951206753     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.12.531     Document Type: Article

References (36)

1. Kirk J.L., Greenfield R.A., Slease R.B., Epstein R.B. Analysis of early infectious complications after autologous bone marrow transplantation. Cancer 1988, 62:2445-2450.
2. Weaver C.H., Schwartzberg L.S., Hainsworth J., et al. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 1997, 19:671-678.
3. Toor A.A., van Burik J.A., Weisdorf D.J. Infections during mobilizing chemotherapy and following autologous stem cell transplantation. Bone Marrow Transplant 2001, 28:1129-1134.
4. Spitzer G., Adkins D.R., Spencer V., et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994, 12:661-670.
5. Klumpp T.R., Mangan K.F., Goldberg S.L., Pearlman E.S., Macdonald J.S. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995, 13:1323-1327.
6. McQuaker I.G., Hunter A.E., Pacey S., Haynes A.P., Iqbal A., Russell N.H. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997, 15:451-457.
7. Tarella C., Castellino C., Locatelli F., et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998, 21:401-407.
8. Linch D.C., Milligan D.W., Winfield D.A., et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997, 99:933-938.
9. Hornedo J., Sola C., Solano C., et al. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant 2002, 29:737-743.
10. Stinson T.J., Adams J.R., Bishop M.R., Kruse S., Tarantolo S., Bennet C.L. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplant 2000, 26:663-666.
11. Schmitz N., Dreger P., Zander A.R., et al. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995, 15:261-266.
12. Delgado C., Francis G.E., Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992, 9:249-304.
13. Johnston E., Crawford J., Blackwell S., et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000, 18:2522-2528.
14. Holmes F.A., O'Shaughnessy J.A., Vukelja S., et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002, 20:727-731.
15. Jagasia M.H., Greer J.P., Morgan D.S., et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 2005, 35:1165-1169.
16. Martino M., Praticò G., Messina G., et al. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006, 77:410-415.
17. Fenk R., Hieronimus N., Steidl U., et al. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 2006, 34:1296-1302.
18. Vanstraelen G., Frere P., Ngirabacu M.C., Willems E., Fillet G., Beguin Y. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 2006, 34:382-388.
19. Ballestrero A., Boy D., Gonella R., et al. Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Ann Hematol 2008, 87:49-55.
20. Schmitz N., Linch D.C., Dreger P., et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996, 347:353-357.
21. Cottler-Fox M.H., Lapidot T., Petit I., et al. Stem cell mobilization. Hematology 2003, 2003:419-437.
22. Rowley S.D., Feng Z., Chen L., et al. A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch. Bone Marrow Transplant 2003, 31:1043-1051.
23. Saral R., Burns W.H., Laskin O.L., Santos G.W., Lietman P.S. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981, 305:63-67.
24. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007, 78:275-282.
25. Menichetti F., Felicini R., Bucaneve G., et al. Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation. Bone Marrow Transplant 1989, 4:489-492.
26. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
27. Dwyre D.M., Holland P.V. Transfusion-associated graft-versus-host disease. Vox Sang 2008, 95:85-93.
28. Green M.D., Koelbl H., Baselga J., et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003, 14:29-35.
29. Farese A.M., Yang B.B., Roskos L., Stead R.B., MacVittie T.J. Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques. Bone Marrow Transplant 2003, 32:399-404.
30. Musto P., Rosario Scalzulli P., Melillo L., et al. Peg-filgrastim after autologous peripheral blood stem cell transplantation in hematological malignancies. ASH Annu Meet Abstr 2004, 104:5200.
31. Staber P.B., Holub R., Linkesch W., Schmidt H., Neumeister P. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2005, 35:889-893.
32. Bruns I., Steidl U., Fischer J.C., et al. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica 2008, 93:347-355.
33. Porrata L.F., Litzow M.R., Tefferi A., et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002, 16:1311-1318.
34. Porrata L.F., Gertz M.A., Inwards D.J., et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001, 98:579-585.
35. Faucher C., Le Corroller A.G., Chabannon C., et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996, 17:533-536.
36. de Azevedo A.M., Nucci M., Maiolino A., et al. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002, 29:745-751.